MINI FUTURE SHORT - ELI LILLY & CO | Market Closed - Börse Stuttgart 15:42:08 2024-07-01 EDT | ||
| 13.09 EUR | -2.39% |
|
| Current month | -2.39% | ||
| 1 month | -39.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 13.09 | -2.39% |
| 24-06-28 | 13.41 | -2.33% |
| 24-06-27 | 13.73 | -4.19% |
| 24-06-26 | 14.33 | +1.49% |
| 24-06-25 | 14.12 | -5.11% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 03:42 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC68CR |
| ISIN | DE000PC68CR6 |
| Date issued | 2024-03-25 |
| Strike | 1,052 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 25.39 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.91 € |
|---|---|
| Lowest since issue | 12.95 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.97%
- Stock Market
- Certificates
- Certificat
